Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
99 pending office actions • 56 art units • 90 examiners • 1 of 99 (1%) have an AI response strategy ready • 80 patents granted in the last 365 days
Genentech Inc. is overseeing 99 pending office actions in the Biotechnology & Pharmaceuticals technology area. This portfolio is remarkably diverse, spanning 44 distinct art units. The prosecution involves 90 distinct examiners, which suggests that the company's intellectual property is being scrutinized by a large and varied group of patent office personnel across these 99 pending actions. Managing 99 actions across 44 art units requires a highly organized approach to address the different technical standards and examiner behaviors encountered.
NGUYEN, TUAN HOANG is the busiest examiner for this portfolio, with 2 pending office actions. The ratio of 99 pending actions to 90 examiners indicates that the vast majority of examiners are only reviewing few applications for the company. Practitioners must be prepared to engage with 90 distinct examiners to advance the company's 99 pending matters. The presence of 44 distinct art units highlights the broad technical scope of the company's current filings. Success in this portfolio depends on the ability to coordinate across 44 art units and address the individual tendencies of 90 different examiners.
Based on the USPTO statutory response window for each pending office action. 30 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 30 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (1%) |
| §101 + other | 9 (9%) |
| §103 only | 27 (27%) |
| §102 only | 5 (5%) |
| §112 only | 11 (11%) |
| Double-patenting only | 1 (1%) |
| Double-patenting + other | 15 (15%) |
| Multi-statute (no §101) | 28 (28%) |
| No statute on record | 2 (2%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NGUYEN, TUAN HOANG | 2 | 90.5% | +4.0% |
| GUSTILO, ESTELLA M | 2 | 53.6% | +34.5% |
| RODRIGUEZ, RAYNA B | 2 | 33.6% | +19.2% |
| BELYAVSKYI, MICHAIL A | 2 | 64.2% | +27.6% |
| KIM, YUNSOO | 2 | 65.9% | +34.2% |
| JARRETT, LORE RAMILLANO | 2 | 68.6% | +25.1% |
| GAO, ASHLEY HARTMAN | 2 | 56.7% | +38.2% |
| GODDARD, LAURA B | 2 | 50.9% | +13.5% |
| BOESEN, CHRISTIAN C | 2 | 75.9% | +21.1% |
| TAYLOR, LIA ELAN | 1 | 64.4% | +29.4% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18911076 | ANOMALY DETECTION IN MEDICAL IMAGING DATA | NGUYEN, TUAN HOANG | — |
| 18909867 | PATHOLOGICAL RESPONSE CALCULATION AND ASSESSMENT TOOL | NGUYEN, TUAN HOANG | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17378651 | ATTENTION-BASED NEURAL NETWORK TO PREDICT PEPTIDE BINDING, PRESENTATION, AND IMMUNOGENICITY | BAILEY, STEVEN WILLIAM | 396d overdue |
| 17964325 | METHOD FOR MEDIUM TREATMENT BEFORE INOCULATION | MOSS, NATALIE M | 127d overdue |
| 18523284 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | SHIAO, REI TSANG | 91d overdue |
| 17351451 | TARGETED INTEGRATION OF NUCLEIC ACIDS | GODDARD, LAURA B | 84d overdue |
| 17075238 | OVERLOAD AND ELUTE CHROMATOGRAPHY | STONEBRAKER, ALYSSA RAE | 72d overdue |
| 18315450 | SMALL PARTS CLEANING APPARATUS AND METHODS OF USE | LEE, KEVIN G | 58d overdue |
| 17172528 | CELL CULTURE STRATEGIES FOR MODULATING PROTEIN GLYCOSYLATION | AFREMOVA, VERA | 49d overdue |
| 18627251 | BIOLOGICAL CONTEXT FOR ANALYZING WHOLE SLIDE IMAGES | ROSARIO, DENNIS | 31d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17351451 | TARGETED INTEGRATION OF NUCLEIC ACIDS | GODDARD, LAURA B | 84d overdue |
| 18048986 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES | GODDARD, LAURA B | 10d overdue |
| 19409123 | CELL CULTURE COMPOSITIONS AND METHODS FOR POLYPEPTIDE PRODUCTION | TAYLOR, LIA ELAN | — |
| 18799503 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR BLADDER CANCER | GUSTILO, ESTELLA M | — |
| 18785844 | CDK INHIBITORS | RODRIGUEZ, RAYNA B | — |
| 18651221 | CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION | BELYAVSKYI, MICHAIL A | — |
| 18636947 | CELL-BASED ASSAY FOR DETECTING ANTl-CD3 HOMODIMERS | BELYAVSKYI, MICHAIL A | — |
| 18600194 | PHARMACEUTICAL COMPOSITIONS OF MOSUNETUZUMAB AND METHODS OF USE | KIM, YUNSOO | — |
| Art Unit | Apps |
|---|---|
| 1644 | 7 |
| 1641 | 5 |
| 1642 | 5 |
| 1646 | 4 |
| 1687 | 4 |
| 1622 | 3 |
| 1621 | 3 |
| 1628 | 3 |
| 1678 | 3 |
| 1643 | 3 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19409123 | CELL CULTURE COMPOSITIONS AND METHODS FOR POLYPEPTIDE PRODUCTION | TAYLOR, LIA ELAN | 1641 | §103 | Final Rejection | — | Pending | Dec 04, 2025 |
| 19029418 | DEEP LEARNING FOR NEW AND ENLARGING LESIONS | USTARIS, JOSEPH G | 2483 | §103 | Non-Final OA | — | Pending | Jan 17, 2025 |
| 18981116 | DETECTING LONGITUDINAL PROGRESSION OF ALZHEIMER'S DISEASE (AD) BASED ON SPEECH ANALYSES | SAINT CYR, LEONARD | 2658 | §103 | Non-Final OA | — | Pending | Dec 13, 2024 |
| 18981081 | MICROSCOPE SLIDE IMAGE-BASED MACHINE LEARNING IMAGE ANALYSIS FOR INFLAMMATORY BOWEL DISEASE | SALEH, ZAID MUHAMMAD | 2668 | §102§103 | Non-Final OA | — | Pending | Dec 13, 2024 |
| 18939497 | MACHINE LEARNING ENABLED DIAGNOSIS AND LESION LOCALIZATION FOR NASCENT GEOGRAPHIC ATROPHY IN AGE-RELATED MACULAR DEGENERATION | YANG, WEI WEN | 2662 | §102§103 | Non-Final OA | — | Pending | Nov 06, 2024 |
| 18933358 | BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS | HALVORSON, MARK | 1646 | §103Other | Non-Final OA | — | Pending | Oct 31, 2024 |
| 18929474 | MACHINE LEARNING ENABLED HEPATOCELLULAR CARCINOMA MOLECULAR SUBTYPE CLASSIFICATION | DHOOGE, DEVIN J | 2677 | §103 | Non-Final OA | — | Pending | Oct 28, 2024 |
| 18859952 | DRUG PRODUCTION METHOD | GAVIN, KRISTIN ELIZABETH | 3624 | §101§103 | Non-Final OA | 40d | Pending | Oct 24, 2024 |
| 18859397 | SOLID FORM OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3- FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9- TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL TARTRATE | WELLS, LAUREN QUINLAN | 1622 | §103§112DP | Non-Final OA | — | Pending | Oct 23, 2024 |
| 18911076 | ANOMALY DETECTION IN MEDICAL IMAGING DATA | NGUYEN, TUAN HOANG | 2649 | DP | Non-Final OA | — | Pending | Oct 09, 2024 |
| 18909867 | PATHOLOGICAL RESPONSE CALCULATION AND ASSESSMENT TOOL | NGUYEN, TUAN HOANG | 2649 | §103Other | Non-Final OA | — | Pending | Oct 08, 2024 |
| 18846553 | DETERMINING A PATIENT’S RESPONSE TO A TREATMENT IN MULTIPLE MYELOMA | LEE, ANDREW ELDRIDGE | 3684 | §101§103 | Final Rejection | — | Pending | Sep 12, 2024 |
| 18820925 | PRODUCTION OF PROTEINS IN GLUTAMINE-FREE CELL CULTURE MEDIA | MOEHLMAN, ANDREW TERRY | 1655 | §112 | Non-Final OA | — | Pending | Aug 30, 2024 |
| 18817828 | TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN ATP COMPETITIVE AKT INHIBITOR, A CDK4/6 INHIBITOR, AND FULVESTRANT | KOSTURKO, GEORGE W | 1621 | §102§103DP | Non-Final OA | — | Pending | Aug 28, 2024 |
| 18799503 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR BLADDER CANCER | GUSTILO, ESTELLA M | 1646 | §102§103§112Other | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18793023 | DOSAGE FORM COMPOSITIONS COMPRISING AN INHIBITOR OF BRUTON'S TYROSINE KINASE | HOWELL, THEODORE R | 1628 | §103DP | Non-Final OA | — | Pending | Aug 02, 2024 |
| 18785844 | CDK INHIBITORS | RODRIGUEZ, RAYNA B | 1628 | §112Other | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18771363 | OVARIAN TOXICITY ASSESSMENT IN HISTOPATHOLOGICAL IMAGES USING DEEP LEARNING | NGUYEN, KHAI MINH | 2641 | §103Other | Non-Final OA | — | Pending | Jul 12, 2024 |
| 18752501 | MULTI-VECTOR RECOMBINASE MEDIATED CASSETTE EXCHANGE | KONOPKA, CATHERINE ANNE | 1635 | §103§112DP | Non-Final OA | 78d overdue | Pending | Jun 24, 2024 |
| 18734329 | SOLID FORMULATIONS COMPRISING AN INHIBITOR OF THE K-RAS PROTEIN HAVING A G12C MUTATION, AND A PROCESS FOR PREPARING | PALLAY, MICHAEL B | 1617 | §103§112 | Non-Final OA | — | Pending | Jun 05, 2024 |
| 18669218 | SYNTHETIC CONTROLS FOR IMMUNOHISTOCHEMISTRY | NGUYEN, NAM P | 1678 | §103 | Non-Final OA | 22d overdue | Pending | May 20, 2024 |
| 18668774 | METHODS OF TREATING CANCER WITH PI3K INHIBITOR, GDC-0077 | BAEK, BONG-SOOK | 1611 | §103Other | Non-Final OA | — | Pending | May 20, 2024 |
| 18710130 | BRM DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | MCKOY, QUINCY ANDRE | 1626 | §102§112 | Non-Final OA | — | Pending | May 14, 2024 |
| 18651221 | CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION | BELYAVSKYI, MICHAIL A | 1644 | §102 | Non-Final OA | — | Pending | Apr 30, 2024 |
| 18642305 | HIGH-THROUGHPUT METHODS FOR PREPARING LIPID NANOPARTICLES AND USES THEREOF | MITCHELL, EDWIN COLEMAN | 1619 | §102§103§112DP | Non-Final OA | — | Pending | Apr 22, 2024 |
| 18636947 | CELL-BASED ASSAY FOR DETECTING ANTl-CD3 HOMODIMERS | BELYAVSKYI, MICHAIL A | 1644 | §102Other | Non-Final OA | — | Pending | Apr 16, 2024 |
| 18698664 | CYCLOPENTYLPYRAZOLE CDK2 INHIBITORS | MARTIN, KEVIN STEPHEN | 1624 | §102§103 | Final Rejection | — | Pending | Apr 04, 2024 |
| 18627251 | BIOLOGICAL CONTEXT FOR ANALYZING WHOLE SLIDE IMAGES | ROSARIO, DENNIS | 2676 | §101§103 | Final Rejection | 31d overdue | Pending | Apr 04, 2024 |
| 18612141 | USES OF IL-13 ANTAGONISTS FOR TREATING ATOPIC DERMATITIS | CHATTIN, AMY MARIE | 1643 | §103DP | Non-Final OA | — | Pending | Mar 21, 2024 |
| 18611567 | DATA QUALITY CONTROL AND INTEGRATION FOR DIGITAL PATHOLOGY | RAJAPUTRA, SUMAN | 2172 | §101§103 | Non-Final OA | — | Pending | Mar 20, 2024 |
| 18604429 | METABOLOMIC ANALYSIS | FRITCHMAN, REBECCA M | 1758 | §112 | Non-Final OA | — | Pending | Mar 13, 2024 |
| 18600194 | PHARMACEUTICAL COMPOSITIONS OF MOSUNETUZUMAB AND METHODS OF USE | KIM, YUNSOO | 1641 | §103DP | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18593665 | ION EXCHANGE MEMBRANE CHROMATOGRAPHY | PUTTLITZ, KARL J | 1644 | §112DP | Non-Final OA | — | Pending | Mar 01, 2024 |
| 18590267 | METHOD FOR TREATING MULTIPLE SCLEROSIS | WEN, SHARON X | 1641 | §102§112DP | Non-Final OA | — | Pending | Feb 28, 2024 |
| 18587251 | METHODS OF TREATING TAU PATHOLOGIES | JUEDES, AMY E | 1644 | §102DP | Non-Final OA | — | Pending | Feb 26, 2024 |
| 18584311 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | YOO, SUN JAE | 1621 | §102 | Non-Final OA | — | Pending | Feb 22, 2024 |
| 18431838 | METHOD AND APPARATUS FOR BIOLOGICAL CELL HARVESTING | COOLEY, CHARLES E | 1774 | §103 | Non-Final OA | — | Pending | Feb 02, 2024 |
| 18429055 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | MACFARLANE, STACEY NEE | 1675 | §102§112DP | Non-Final OA | — | Pending | Jan 31, 2024 |
| 18417787 | BRAIN TARGETING COMPOSITIONS AND METHODS OF USE THEREOF | BUTTICE, AUDREY L | 1647 | §103§112 | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18416031 | Anti-Jagged1 Antibodies and Methods of Use | GUSTILO, ESTELLA M | 1646 | §112DP | Non-Final OA | — | Pending | Jan 18, 2024 |
| 18412348 | AUTOMATED DIGITAL ASSESSMENT OF HISTOLOGIC SAMPLES | CRUZ, IRIANA | 2681 | §103 | Non-Final OA | — | Pending | Jan 12, 2024 |
| 18410827 | MINICOLUMN RETAINING APPARATUS AND METHOD OF USE | JARRETT, LORE RAMILLANO | 1797 | §102§103 | Non-Final OA | — | Pending | Jan 11, 2024 |
| 18544236 | METHODS OF TREATING CANCER USING B-RAF INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS | RODRIGUEZ, RAYNA B | 1628 | §103 | Final Rejection | — | Pending | Dec 18, 2023 |
| 18540310 | EGFR INHIBITOR AND PERK ACTIVATOR IN COMBINATION THERAPY AND THEIR USE FOR TREATING CANCER | DEKARSKE, MADELINE MCGUIRE | 1622 | §103§112 | Non-Final OA | — | Pending | Dec 14, 2023 |
| 18523284 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | SHIAO, REI TSANG | 1691 | §103§112 | Non-Final OA | 91d overdue | AI Ready | Nov 29, 2023 |
| 18516552 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | SCHMITT, MICHAEL J | 1629 | §103Other | Non-Final OA | 55d | Pending | Nov 21, 2023 |
| 18514280 | MODIFIED CELLS FOR THE PRODUCTION OF A RECOMBINANT PRODUCT OF INTEREST | MCKNIGHT, CIARA A | 1656 | §103§112 | Non-Final OA | — | Pending | Nov 20, 2023 |
| 18510297 | COMBINED TRANSPOSON-MEDIATED INTEGRATION AND TARGETED INTEGRATION OF NUCLEIC ACIDS INTO HOST CELLS | MEYERING, SHABANA SHABBEER | 1635 | §103§112DP | Non-Final OA | — | Pending | Nov 15, 2023 |
| 18504041 | ANTI-LY6G6D ANTIBODIES AND METHODS OF USE | MOSELEY II, NELSON B | 1642 | Other | Non-Final OA | — | Pending | Nov 07, 2023 |
| 18486325 | IN VITRO CELL-BASED ASSAY FOR PREDICTING PHARMACOKINETICS AND BRAIN PENETRATION OF BIOLOGICS | HOFFMAN, ALEXANDER JOSEPH | 1677 | §103§112 | Non-Final OA | — | Pending | Oct 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGenentech Inc. has 99 pending office actions as of October 2026, spread across 56 art units and 90 examiners.
Tuan Hoang Nguyen has the most, with 2 of Genentech Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.